ADX-324
- Generic Name
- ADX-324
Efficacy, Safety, PK, PD and HRQoL of 2 Dose Levels and Regimens of ADX-324 in Preventing HAE Attacks Compared With Placebo in Participants With Type 1 and Type II HAE
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06960213
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05691361
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath